Recombinant Human LRIG3 protein (rFc Tag)

• Home
• Products
• Fusion Proteins
• AuthentiKine ELISA Kits
• Recombinant Human LRIG3 protein (rFc Tag) (Eg2853)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

rFc Tag

Activity

not tested

Cat no : Eg2853

---

Validation Data Gallery

• 

  Purity of Recombinant Human LRIG3 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Human LRIG3 protein Asp28-Thr807 (Accession# Q6UXM1-1) with a rabbit Fc tag at the C-terminus.
• GeneID: 121227
• Accession: Q6UXM1-1
• PredictedSize: 112.6 kDa
• SDS-PAGE: 112-120 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

LRIG3, or leucine-rich repeats and immunoglobulin-like domains 3, is a member of the LRIG family of transmembrane proteins. LRIG3 is known to play a role in the regulation of growth factor receptor signaling, which includes receptor tyrosine and serine/threonine kinases. LRIG3 has been implicated in various biological processes, including the regulation of tumor growth and angiogenesis. It has been reported that LRIG3 can act as a tumor suppressor in glioblastoma multiforme (GBM), where it modulates the proliferation, migration, and invasion of glioma cells by targeting the EGFR and MET signaling pathways.

References:

1. Simion C, et al. (2014). Endocr Relat Cancer. 21(6):R431-43.
2. Peng C, et al. (2021). Front Oncol.11:621154.